TD Asset Management
CORT icon

TD Asset Management’s Corcept Therapeutics CORT Stock Holding History

TD Asset Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-994,844
Closed -$34.6M – 1247
2025
Q4 		$34.6M Buy
994,844
+38,708
+4% +$3.04M 0.03% 392
2025
Q3 		$79.5M Buy
956,136
+136,254
+17% +$9.86M 0.06% 234
2025
Q2 		$60.2M Buy
+819,882
New +$59.4M 0.05% 275
2022
Q4 		– Sell
-994,297
Closed -$25.4M – 1457
2022
Q3 		$25.4M Buy
994,297
+33,849
+4% +$906K 0.03% 370
2022
Q2 		$22.8M Hold
960,448
– – 0.03% 404
2022
Q1 		$21.6M Sell
960,448
-201,840
-17% -$4.29M 0.02% 458
2021
Q4 		$23M Buy
1,162,288
+254,667
+28% +$5.17M 0.02% 483
2021
Q3 		$17.9M Hold
907,621
– – 0.02% 498
2021
Q2 		$18.9M Buy
907,621
+737,825
+435% +$16.4M 0.02% 493
2021
Q1 		$4.04M Buy
+169,796
New +$4.53M ﹤0.01% 890

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

TD Asset Management's CORT Position: Q1 2026 in Review

TD Asset Management sold out of Corcept Therapeutics (CORT) in Q1 2026, closing a stake of 994,844 shares — an estimated $34.6M sold.

TD Asset Management first reported a position in CORT in Q1 2021 and held it in 10 quarters. The position peaked at $79.5M in Q3 2025. 351 funds tracked by Wall St. Rank hold CORT as of Q1 2026.

  • TD Asset Management reported no remaining Corcept Therapeutics position as of Q1 2026 after selling out during the quarter.
  • TD Asset Management sold 994,844 Corcept Therapeutics shares in Q1 2026, an estimated $34.6M.
  • TD Asset Management first reported a position in Corcept Therapeutics in Q1 2021 and held it in 10 quarters.
  • TD Asset Management's Corcept Therapeutics position peaked at $79.5M in Q3 2025.
  • 351 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2026.

Based on TD Asset Management's 13F filing for Q1 2026, filed 11 May 2026.